| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2011 | EP2287183A1 Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity |
| 02/23/2011 | EP2287173A1 10a-azalide compound having 4-membered ring structure |
| 02/23/2011 | EP2287167A1 Polycyclic agents for the treatment of respiratory syncytial virus infections |
| 02/23/2011 | EP2287166A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/23/2011 | EP2287165A2 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| 02/23/2011 | EP2287164A1 Process for the manufacture of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
| 02/23/2011 | EP2287163A1 2-amino-3-sulphonyl-tetrahydro-pyrazolo[1,5-a]pyrido-pyrimidine antagonists of serotonin 5-ht6 receptors, methods for the production and use thereof |
| 02/23/2011 | EP2287162A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders |
| 02/23/2011 | EP2287161A1 Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders |
| 02/23/2011 | EP2287160A1 Novel benzothiophene oxide derivative and salt thereof |
| 02/23/2011 | EP2287159A1 New bicyclic dioxanes, their preparation and their use as organoleptic compounds |
| 02/23/2011 | EP2287156A1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| 02/23/2011 | EP2287155A1 Acylthiourea compound or salt thereof, and use of the compound or the salt |
| 02/23/2011 | EP2287154A1 Efficient synthesis for the preparation of montelukast |
| 02/23/2011 | EP2287150A2 Substituted tetracycline compounds |
| 02/23/2011 | EP2287148A2 Substituted tetracycline compounds |
| 02/23/2011 | EP2287147A2 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative |
| 02/23/2011 | EP2287140A2 Substituted tetracycline compounds |
| 02/23/2011 | EP2286876A1 Parasiticidal composition |
| 02/23/2011 | EP2286875A1 Use of ansamycins for treatment or prevention of Alzheimer's Disease |
| 02/23/2011 | EP2286848A2 Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis |
| 02/23/2011 | EP2286840A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286839A2 Treatment of obesity and related diseases |
| 02/23/2011 | EP2286838A2 Treatment of obesity and related disorders |
| 02/23/2011 | EP2286837A2 Treatment of obesity and obesity related diseases |
| 02/23/2011 | EP2286836A1 Immunostimulating agent |
| 02/23/2011 | EP2286827A1 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 02/23/2011 | EP2286826A2 Treatment of tumor metastase and cancer |
| 02/23/2011 | EP2286820A1 Buffered Compositions for dialysis |
| 02/23/2011 | EP2286819A1 Pharmceuttical composition for treating cardio-cerebro vascular diseases and preparative method and kit thereof |
| 02/23/2011 | EP2286818A1 Fulvestrant formulation |
| 02/23/2011 | EP2286817A2 Method of treating functional bowel disorders |
| 02/23/2011 | EP2286816A1 Method of treating atherosclerosis, dyslipidemias and related conditions |
| 02/23/2011 | EP2286815A2 Methylphenidate Modified Release Formulations |
| 02/23/2011 | EP2286814A1 Transdermal preparation containing palonosetron |
| 02/23/2011 | EP2286813A2 Use of naphthyridine derivatives as medicaments |
| 02/23/2011 | EP2286812A1 Solubilized topoisomerase poisons |
| 02/23/2011 | EP2286811A1 Chemokine receptor antagonists and methods of use thereof |
| 02/23/2011 | EP2286810A1 Pharmaceutical composition for treatment of fibromyalgia |
| 02/23/2011 | EP2286809A1 Personalised pharmaceutical composition containing retinoic acid, for anti-aging of the skin |
| 02/23/2011 | EP2286808A1 Cytohesin inhibitors |
| 02/23/2011 | EP2286807A2 Medicament for preventive and/or therapeutic treatment of adhesion of bowel |
| 02/23/2011 | EP2286806A1 Solid formulations of ospemifene |
| 02/23/2011 | EP2286805A1 Infant formula compositions containing lutein and zeaxanthin |
| 02/23/2011 | EP2286804A1 A method of treating degenerative disc disease |
| 02/23/2011 | EP2286803A1 Use of alpha1 adrenergic receptor antagonists for treatment or prevention of Alzheimer's Disease |
| 02/23/2011 | EP2286802A1 Transdermal therapeutic system |
| 02/23/2011 | EP2286801A2 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/23/2011 | EP2286800A1 Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs |
| 02/23/2011 | EP2286799A2 Microspheres for active embolization |
| 02/23/2011 | EP2286798A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| 02/23/2011 | EP2286797A2 Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
| 02/23/2011 | EP2286796A2 Controlled release formulation comprising albuterol |
| 02/23/2011 | EP2286795A1 Method of producing a cationic liposomal preparation comprising a lipophilic compound |
| 02/23/2011 | EP2286794A1 Use of cationic liposomes comprising an active drug |
| 02/23/2011 | EP2286793A2 Pharmaceutical formulations comprising cannabidiol |
| 02/23/2011 | EP2286676A1 Method for treatment of chronic venous insufficiencies using an extract of red vine leaves |
| 02/23/2011 | EP2286675A1 Composition for promotion of bone growth and maintenance of bone health |
| 02/23/2011 | EP2286669A1 Flavanones-containing food compositions |
| 02/23/2011 | EP2286666A1 Versatile disinfectant |
| 02/23/2011 | EP2286663A2 Methods and compositions for treating ectoparasite infestation |
| 02/23/2011 | EP2286224A1 Method for improving cardiovascular risk profile of cox inhibitors |
| 02/23/2011 | EP2285961A1 Oligonucleotides for treating inflammation and neoplastic cell proliferation |
| 02/23/2011 | EP2285960A2 Compositions and methods related to mirna modulation of neovascularization or angiogenesis |
| 02/23/2011 | EP2285820A1 Intercalating triplexes and duplexes using aryl naphthoimidazol and process for the preparation thereof |
| 02/23/2011 | EP2285819A1 Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
| 02/23/2011 | EP2285817A2 Novel uses of d-mannopyranose derivatives activating angiogenesis |
| 02/23/2011 | EP2285812A1 HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION |
| 02/23/2011 | EP2285811A1 3-(3-pyrimidin-2-yl-benzyl)-ý1,2,4¨triazoloý4,3-b¨pyridazine derivatives as met kinase inhibitors |
| 02/23/2011 | EP2285810A1 Selective ligands for the neuronal nicotinic receptors and uses thereof |
| 02/23/2011 | EP2285809A1 1,4-diaryl-pyrimidopyridazine-2,5-diones and their use |
| 02/23/2011 | EP2285808A1 Spiro-indole derivatives for the treatment of parasitic diseases |
| 02/23/2011 | EP2285807A1 Heterocyclic antiviral compounds |
| 02/23/2011 | EP2285805A1 Aryl-quinolyl compounds and their use |
| 02/23/2011 | EP2285803A1 5-lipoxygenase-activating protein inhibitor |
| 02/23/2011 | EP2285802A1 Oxo-imidazolyl compounds having antibacterial activity |
| 02/23/2011 | EP2285800A1 Quinoline or isoquinoline substituted p2x7 antagonists |
| 02/23/2011 | EP2285798A1 Muscarinic receptor agonits useful in the treatment of pain, alzheimer's disease and schizophrenia |
| 02/23/2011 | EP2285797A1 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors |
| 02/23/2011 | EP2285796A1 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
| 02/23/2011 | EP2285794A2 Chromane derivatives as trpv3 modulators |
| 02/23/2011 | EP2285790A1 Therapeutic compounds |
| 02/23/2011 | EP2285788A1 New terpenes and macrocycles |
| 02/23/2011 | EP2285787A2 3-substituted propanamine compounds |
| 02/23/2011 | EP2285786A1 Quinoxalinedione derivatives |
| 02/23/2011 | EP2285785A1 3,5-diamino-6-chloro-pyrazine-2-carboxylic acid derivatives and their use as epithelial sodium channel blockers for the treatment of arway diseases |
| 02/23/2011 | EP2285784A1 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| 02/23/2011 | EP2285783A1 Indazole compounds as ccr1 receptor antagonists |
| 02/23/2011 | EP2285781A1 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors |
| 02/23/2011 | EP2285780A1 Processes and compounds for the preparation of normorphinans |
| 02/23/2011 | EP2285775A1 Therapeutic lactams |
| 02/23/2011 | EP2285770A1 Process for the synthesis of arformoterol |
| 02/23/2011 | EP2285769A1 A process for the preparation of enantiomerically pure amines |
| 02/23/2011 | EP2285767A2 Stabilization of the composition of a mixture |
| 02/23/2011 | EP2285420A2 Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
| 02/23/2011 | EP2285419A1 Hepatoprotectant acetaminophen mutual prodrugs |
| 02/23/2011 | EP2285413A2 A pharmaceutical composition |
| 02/23/2011 | EP2285411A1 Nicotine lozenge compositions |
| 02/23/2011 | EP2285406A2 Inhibitory effects of nordihydroguaiaretic acid (ndga) on the igf-1 receptor and androgen dependent growth of lapc-4 prostate cancer cells |
| 02/23/2011 | EP2285402A2 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |